secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2026-05-13T20:05:56+00:00
Accession:  0001437749-26-016717
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma Q3 net loss $5.6M; EXXUA launch revenue $2.4M
------------------------------------------------------------

- Net revenue $12.4M, down 33% YoY from $18.5M; net loss $5.6M vs net income $4.0M.
- EXXUA (gepirone) contributed $2.4M net revenue; over 1,300 prescriptions from 450 prescribers in partial quarter.
- ADHD Portfolio $9.1M (-41% YoY) due to sales force shift to EXXUA and generic competition for Adzenys XR-ODT.
- Adjusted EBITDA -$2.8M vs $3.9M YoY; warrant amendment reduced derivative liabilities by $26.4M, boosting equity.
- Cash $26.7M at March 31, 2026, down from $31.0M at June 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774926016717/0001437749-26-016717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774926016717/aytu20260209_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-016717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer